Search

Your search keyword '"Barr, Paul"' showing total 2,746 results
Start Over Author "Barr, Paul"
2,746 results on '"Barr, Paul"'

51. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia

Author

Kipps, Thomas J., Fraser, Graeme, Coutre, Steven E., Brown, Jennifer R., Barrientos, Jacqueline C., Barr, Paul M., Byrd, John C., O’Brien, Susan M., Dilhuydy, Marie-Sarah, Hillmen, Peter, Jaeger, Ulrich, Moreno, Carol, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher A., Mahler, Michelle, Salman, Mariya, Eckert, Karl, Solman, Isabelle G., Balasubramanian, Sriram, Cheng, Mei, Londhe, Anil, Ninomoto, Joi, Howes, Angela, James, Danelle F., and Hallek, Michael

Published
2019
Full Text
View/download PDF

58. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

Author

Byrd, John C, Brown, Jennifer R, O'Brien, Susan, Barrientos, Jacqueline C, Kay, Neil E, Reddy, Nishitha M, Coutre, Steven, Tam, Constantine S, Mulligan, Stephen P, Jaeger, Ulrich, Devereux, Steve, Barr, Paul M, Furman, Richard R, Kipps, Thomas J, Cymbalista, Florence, Pocock, Christopher, Thornton, Patrick, Caligaris-Cappio, Federico, Robak, Tadeusz, Delgado, Julio, Schuster, Stephen J, Montillo, Marco, Schuh, Anna, de Vos, Sven, Gill, Devinder, Bloor, Adrian, Dearden, Claire, Moreno, Carol, Jones, Jeffrey J, Chu, Alvina D, Fardis, Maria, McGreivy, Jesse, Clow, Fong, James, Danelle F, and Hillmen, Peter

Subjects
Lymphoma, Rare Diseases, Orphan Drug, Clinical Research, Hematology, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adenine, Adult, Agammaglobulinaemia Tyrosine Kinase, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Cough, Diarrhea, Disease-Free Survival, Fatigue, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Survival Rate, RESONATE Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundIn patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.MethodsIn this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab. The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points.ResultsAt a median follow-up of 9.4 months, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 months), as compared with a median of 8.1 months in the ofatumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P

Published
2014

59. Family Caregiver Comfort with Telehealth Technologies: Differences by Race and Ethnicity in a Cross-Sectional Survey.

Author

Bratches, Reed W.R., Onsando, Wambui, Puga, Frank, Odom, J. Nicholas, and Barr, Paul J.

Subjects
CAREGIVERS, RACIAL differences, TELEMEDICINE, COVID-19 pandemic, ETHNIC groups
Abstract

Background: Telehealth has seen widespread use since the onset of the COVID-19 pandemic, and 82% patients required assistance in accessing their telehealth appointments. This assistance commonly comes from a family caregiver who may or may not be comfortable using the technologies associated with telehealth. The objective of our study was to analyze a demographically representative survey of U.S. family caregivers to understand the level of comfort using telehealth technologies among family caregivers. Methods: A secondary analysis of survey data collected during the COVID-19 pandemic in 2020. Level of caregiver comfort using computers, smartphones, and tablets was determined through three Likert-style questions. Proportional odds logistic regression was used to understand the associations between demographic variables and level of caregiver comfort using each technology, when adjusting for covariates. Results: A total of 340 caregivers were included in the analysis. Compared with non-Hispanic white caregivers, Asian caregivers had higher odds (odds ratio [OR] 3.14; 95% confidence interval [CI] 1.36, 8.02; p = 0.01) of expressing comfort using computers; black caregivers (OR 0.46; 95% CI 0.21, 0.98; p = 0.04) and Hispanic caregivers (OR 0.36; 95% CI 0.17, 0.79; p = 0.01) expressed lower odds of comfort using smartphones; and Asian caregivers had higher odds (OR 4.64; 95% CI 2.05, 11.69; p = 0.001) of expressing comfort using tablets. Conclusion and Implications: There are identified disparities in the level of technological comfort using computers, smartphones, and tablets by different racial and ethnic groups. Health systems should consider early stakeholder involvement in the design of telehealth technologies, culturally responsive training materials on telehealth technology use to reduce disparities in comfort using telehealth technologies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

61. P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY

Author

Spurgeon, Stephen, primary, Mei, Matthew, additional, Barr, Paul M., additional, Barrientos, Jacqueline, additional, de Vos, Sven, additional, Furman, Richard, additional, Patel, Krish, additional, Thompson, Philip, additional, Choi, Michael Y., additional, Kallam, Avyakta, additional, Wang, Siruo, additional, Ogbu, Uzor, additional, Marinello, Patricia, additional, and Wang, Michael, additional

Published
2023
Full Text
View/download PDF

62. P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY

Author

Lansigan, Frederick, primary, A. Eyre, Toby, additional, Ghosh, Nilanjan, additional, S. Manzoor, Beenish, additional, C. Coombs, Catherine, additional, Lamanna, Nicole, additional, H. Tuncer, Hande, additional, Emechebe, Dozie, additional, R. Brown, Jennifer, additional, E. Roeker, Lindsey, additional, Ujjani, Chaitra, additional, Alhasani, Hasan, additional, Fleury, Isabelle, additional, A. Leslie, Lori, additional, Skarbnik, Alan, additional, Rhodes, Joanna, additional, T. Hill, Brian, additional, M. Barr, Paul, additional, S. Davids, Matthew, additional, P. Fox, Christopher, additional, Choi, Yun, additional, Schuh, Anna, additional, Kennard, Kaitlin, additional, E. Jensen, Christopher, additional, Jawaid, Dureshahwar, additional, Sharma, Aditya, additional, Pivneva, Irina, additional, Watson, Talissa, additional, and Shadman, Mazyar, additional

Published
2023
Full Text
View/download PDF

63. P617: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4-Y FOLLOW-UP FROM FD COHORT OF PHASE 2 CAPTIVATE STUDY

Author

Ghia, Paolo, primary, Allan, John, additional, Siddiqi, Tanya, additional, Wierda, William G., additional, Tam, Constantine, additional, Moreno, Carol, additional, Tedeschi, Alessandra, additional, Szafer-Glusman, Edith, additional, Zhou, Cathy, additional, Abbazio, Chris, additional, Dean, Jim, additional, Szoke, Anita, additional, and Barr, Paul M., additional

Published
2023
Full Text
View/download PDF

66. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma

Author

O'Brien, Susan, Hillmen, Peter, Coutre, Steven, Barr, Paul M., Fraser, Graeme, Tedeschi, Alessandra, Burger, Jan A., Dilhuydy, Marie-Sarah, Hess, Georg, Moreno, Carol, Cramer, Paula, Liu, Emily, Chang, Stephen, Vermeulen, Jessica, Styles, Lori, Howes, Angela, James, Danelle F., Patel, Kalpesh, Graef, Thorsten, and Valentino, Rudolph

Published
2018
Full Text
View/download PDF

72. Data from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

Author

Allan, John N., primary, Flinn, Ian W., primary, Siddiqi, Tanya, primary, Ghia, Paolo, primary, Tam, Constantine S., primary, Kipps, Thomas J., primary, Barr, Paul M., primary, Elinder Camburn, Anna, primary, Tedeschi, Alessandra, primary, Badoux, Xavier C., primary, Jacobs, Ryan, primary, Kuss, Bryone J., primary, Trentin, Livio, primary, Zhou, Cathy, primary, Szoke, Anita, primary, Abbazio, Christopher, primary, and Wierda, William G., primary

Published
2023
Full Text
View/download PDF

73. Supplementary Figure S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

Author

Allan, John N., primary, Flinn, Ian W., primary, Siddiqi, Tanya, primary, Ghia, Paolo, primary, Tam, Constantine S., primary, Kipps, Thomas J., primary, Barr, Paul M., primary, Elinder Camburn, Anna, primary, Tedeschi, Alessandra, primary, Badoux, Xavier C., primary, Jacobs, Ryan, primary, Kuss, Bryone J., primary, Trentin, Livio, primary, Zhou, Cathy, primary, Szoke, Anita, primary, Abbazio, Christopher, primary, and Wierda, William G., primary

Published
2023
Full Text
View/download PDF

74. Supplementary Table S2 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

Author

Allan, John N., primary, Flinn, Ian W., primary, Siddiqi, Tanya, primary, Ghia, Paolo, primary, Tam, Constantine S., primary, Kipps, Thomas J., primary, Barr, Paul M., primary, Elinder Camburn, Anna, primary, Tedeschi, Alessandra, primary, Badoux, Xavier C., primary, Jacobs, Ryan, primary, Kuss, Bryone J., primary, Trentin, Livio, primary, Zhou, Cathy, primary, Szoke, Anita, primary, Abbazio, Christopher, primary, and Wierda, William G., primary

Published
2023
Full Text
View/download PDF

75. First dose infusion reaction during anti-CD20 monoclonal antibody therapy in chronic lymphocytic leukemia associates with high IP-10 levels amid cytokine release syndrome

Author

Chu, Charles C, primary, Moore, Jeremiah E., additional, Bloom, Paige C., additional, Bruno, Jennifer E., additional, Quataert, Sally A., additional, Mosmann, Tim R., additional, Jaimes-Delgadillo, Nydia, additional, Herne, Christine Ann, additional, VanDerMeid, Karl R., additional, Baran, Andrea M., additional, Peterson, Derick R., additional, Taylor, Ronald P, additional, Elliott, Michael Rusty, additional, Wallace, Danielle S., additional, Barr, Paul M., additional, and Zent, Clive S., additional

Published
2023
Full Text
View/download PDF

77. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Author

Barr, Paul M., Brown, Jennifer R., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Mulligan, Stephen P., Jaeger, Ulrich, Furman, Richard R., Cymbalista, Florence, Montillo, Marco, Dearden, Claire, Robak, Tadeusz, Moreno, Carol, Pagel, John M., Burger, Jan A., Suzuki, Samuel, Sukbuntherng, Juthamas, Cole, George, James, Danelle F., and Byrd, John C.

Published
2017
Full Text
View/download PDF

80. Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Author

Shanafelt, Tait D., Wang, Xin Victoria, Hanson, Curtis A., Paietta, Elisabeth, O’Brien, Susan, Barrientos, Jacqueline, Jelinek, Diane F., Braggio, Esteban, Leis, Jose F., Zhang, Cong Christine, Barr, Paul M., Cashen, Amanda F., Mato, Anthony R., Singh, Avina K., Mullane, Michael P., Little, Richard F., Erba, Harry, Stone, Richard M., Litzow, Mark, Tallman, Martin, and Kay, Neil E.

Published
2024
Full Text
View/download PDF

82. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

Author

Mato, Anthony R., Nabhan, Chadi, Barr, Paul M., Ujjani, Chaitra S., Hill, Brian T., Lamanna, Nicole, Skarbnik, Alan P., Howlett, Christina, Pu, Jeffrey J., Sehgal, Alison R., Strelec, Lauren E., Vandegrift, Alexandra, Fitzpatrick, Danielle M., Zent, Clive S., Feldman, Tatyana, Goy, Andre, Claxton, David F., Bachow, Spencer Henick, Kaur, Gurbakhash, Svoboda, Jakub, Nasta, Sunita Dwivedy, Porter, David, Landsburg, Daniel J., Schuster, Stephen J., Cheson, Bruce D., Kiselev, Pavel, and Evens, Andrew M.

Published
2016
Full Text
View/download PDF

83. The feasibility and acceptability of a data science powered personal health library HealthPAL.

Author

Barr, Paul, primary, Oh, Lisa, additional, Ganoe, Craig, additional, Tarczewski, Susan, additional, Carpenter-Song, Elizabeth, additional, James O'Malley, A., additional, Onsando, Wambui, additional, Arend, Roger, additional, Piper, Sheryl, additional, Masel, Meredith, additional, Cavanaugh, Kerri, additional, Das, Amar, additional, and Bruce, Martha, additional

Published
2023
Full Text
View/download PDF

84. Supplementary Data from Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts

Author

Barr, Paul M., primary, Tedeschi, Alessandra, primary, Wierda, William G., primary, Allan, John N., primary, Ghia, Paolo, primary, Vallisa, Daniele, primary, Jacobs, Ryan, primary, O'Brien, Susan, primary, Grigg, Andrew P., primary, Walker, Patricia, primary, Zhou, Cathy, primary, Ninomoto, Joi, primary, Krigsfeld, Gabriel, primary, and Tam, Constantine S., primary

Published
2023
Full Text
View/download PDF

85. Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

Author

Roeker, Lindsey E., primary, Fox, Christopher P., primary, Eyre, Toby A., primary, Brander, Danielle M., primary, Allan, John N., primary, Schuster, Stephen J., primary, Nabhan, Chadi, primary, Hill, Brian T., primary, Shah, Nirav N., primary, Lansigan, Frederick, primary, Yazdy, Maryam, primary, Cheson, Bruce D., primary, Lamanna, Nicole, primary, Singavi, Arun K., primary, Coombs, Catherine C., primary, Barr, Paul M., primary, Skarbnik, Alan P., primary, Shadman, Mazyar, primary, Ujjani, Chaitra S., primary, Tuncer, Hande H., primary, Winter, Allison M., primary, Rhodes, Joanna, primary, Dorsey, Colleen, primary, Morse, Hannah, primary, Kabel, Charlene, primary, Pagel, John M., primary, Williams, Annalynn M., primary, Jacobs, Ryan, primary, Goy, Andre, primary, Muralikrishnan, Sivraj, primary, Pearson, Laurie, primary, Sitlinger, Andrea, primary, Bailey, Neil, primary, Schuh, Anna, primary, Kirkwood, Amy A., primary, and Mato, Anthony R., primary

Published
2023
Full Text
View/download PDF

86. Supplemental Figure 1 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Author

Mato, Anthony R., primary, Roeker, Lindsey E., primary, Jacobs, Ryan, primary, Hill, Brian T., primary, Lamanna, Nicole, primary, Brander, Danielle, primary, Shadman, Mazyar, primary, Ujjani, Chaitra S., primary, Yazdy, Maryam Sarraf, primary, Perini, Guilherme Fleury, primary, Pinilla-Ibarz, Javier A., primary, Barrientos, Jacqueline, primary, Skarbnik, Alan P., primary, Torka, Pallawi, primary, Pu, Jeffrey J., primary, Pagel, John M., primary, Gohil, Satyen, primary, Fakhri, Bita, primary, Choi, Michael, primary, Coombs, Catherine C., primary, Rhodes, Joanna, primary, Barr, Paul M., primary, Portell, Craig A., primary, Parry, Helen, primary, Garcia, Christine A., primary, Whitaker, Kate J., primary, Winter, Allison M., primary, Sitlinger, Andrea, primary, Khajavian, Sirin, primary, Grajales-Cruz, Ariel F., primary, Isaac, Krista M., primary, Shah, Pratik, primary, Akhtar, Othman S., primary, Pocock, Rachael, primary, Lam, Kentson, primary, Voorhees, Timothy J., primary, Schuster, Stephen J., primary, Rodgers, Thomas D., primary, Fox, Christopher P., primary, Martinez-Calle, Nicolas, primary, Munir, Talha, primary, Bhavsar, Erica B., primary, Bailey, Neil, primary, Lee, Jason C., primary, Weissbrot, Hanna B., primary, Nabhan, Chadi, primary, Goodfriend, Julie M., primary, King, Amber C., primary, Zelenetz, Andrew D., primary, Dorsey, Colleen, primary, Bigelow, Kayla, primary, Cheson, Bruce D., primary, Allan, John N., primary, and Eyre, Toby A., primary

Published
2023
Full Text
View/download PDF

87. Supplementary Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

Author

Roeker, Lindsey E., primary, Fox, Christopher P., primary, Eyre, Toby A., primary, Brander, Danielle M., primary, Allan, John N., primary, Schuster, Stephen J., primary, Nabhan, Chadi, primary, Hill, Brian T., primary, Shah, Nirav N., primary, Lansigan, Frederick, primary, Yazdy, Maryam, primary, Cheson, Bruce D., primary, Lamanna, Nicole, primary, Singavi, Arun K., primary, Coombs, Catherine C., primary, Barr, Paul M., primary, Skarbnik, Alan P., primary, Shadman, Mazyar, primary, Ujjani, Chaitra S., primary, Tuncer, Hande H., primary, Winter, Allison M., primary, Rhodes, Joanna, primary, Dorsey, Colleen, primary, Morse, Hannah, primary, Kabel, Charlene, primary, Pagel, John M., primary, Williams, Annalynn M., primary, Jacobs, Ryan, primary, Goy, Andre, primary, Muralikrishnan, Sivraj, primary, Pearson, Laurie, primary, Sitlinger, Andrea, primary, Bailey, Neil, primary, Schuh, Anna, primary, Kirkwood, Amy A., primary, and Mato, Anthony R., primary

Published
2023
Full Text
View/download PDF

88. Supplemental Figure 2 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Author

Mato, Anthony R., primary, Roeker, Lindsey E., primary, Jacobs, Ryan, primary, Hill, Brian T., primary, Lamanna, Nicole, primary, Brander, Danielle, primary, Shadman, Mazyar, primary, Ujjani, Chaitra S., primary, Yazdy, Maryam Sarraf, primary, Perini, Guilherme Fleury, primary, Pinilla-Ibarz, Javier A., primary, Barrientos, Jacqueline, primary, Skarbnik, Alan P., primary, Torka, Pallawi, primary, Pu, Jeffrey J., primary, Pagel, John M., primary, Gohil, Satyen, primary, Fakhri, Bita, primary, Choi, Michael, primary, Coombs, Catherine C., primary, Rhodes, Joanna, primary, Barr, Paul M., primary, Portell, Craig A., primary, Parry, Helen, primary, Garcia, Christine A., primary, Whitaker, Kate J., primary, Winter, Allison M., primary, Sitlinger, Andrea, primary, Khajavian, Sirin, primary, Grajales-Cruz, Ariel F., primary, Isaac, Krista M., primary, Shah, Pratik, primary, Akhtar, Othman S., primary, Pocock, Rachael, primary, Lam, Kentson, primary, Voorhees, Timothy J., primary, Schuster, Stephen J., primary, Rodgers, Thomas D., primary, Fox, Christopher P., primary, Martinez-Calle, Nicolas, primary, Munir, Talha, primary, Bhavsar, Erica B., primary, Bailey, Neil, primary, Lee, Jason C., primary, Weissbrot, Hanna B., primary, Nabhan, Chadi, primary, Goodfriend, Julie M., primary, King, Amber C., primary, Zelenetz, Andrew D., primary, Dorsey, Colleen, primary, Bigelow, Kayla, primary, Cheson, Bruce D., primary, Allan, John N., primary, and Eyre, Toby A., primary

Published
2023
Full Text
View/download PDF

89. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Author

Kumar, Anita, Casulo, Carla, Yahalom, Joachim, Schöder, Heiko, Barr, Paul M., Caron, Philip, Chiu, April, Constine, Louis S., Drullinsky, Pamela, Friedberg, Jonathan W., Gerecitano, John F., Hamilton, Audrey, Hamlin, Paul A., Horwitz, Steven M., Jacob, Alexandra G., Matasar, Matthew J., McArthur, Gianna N., McCall, Susan J., Moskowitz, Alison J., Noy, Ariela, Palomba, Maria L., Portlock, Carol S., Straus, David J., VanderEls, Nicholas, Verwys, Stephanie L., Yang, Joanna, Younes, Anas, Zelenetz, Andrew D., Zhang, Zhigang, and Moskowitz, Craig H.

Published
2016
Full Text
View/download PDF

90. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

Author

Jurinovic, Vindi, Kridel, Robert, Staiger, Annette M., Szczepanowski, Monika, Horn, Heike, Dreyling, Martin H., Rosenwald, Andreas, Ott, German, Klapper, Wolfram, Zelenetz, Andrew D., Barr, Paul M., Friedberg, Jonathan W., Ansell, Stephen, Sehn, Laurie H., Connors, Joseph M., Gascoyne, Randy D., Hiddemann, Wolfgang, Unterhalt, Michael, Weinstock, David M., and Weigert, Oliver

Published
2016
Full Text
View/download PDF

92. Postibrutinib outcomes in patients with mantle cell lymphoma

Author

Martin, Peter, Maddocks, Kami, Leonard, John P., Ruan, Jia, Goy, Andre, Wagner-Johnston, Nina, Rule, Simon, Advani, Ranjana, Iberri, David, Phillips, Tycel, Spurgeon, Stephen, Kozin, Eliana, Noto, Katherine, Chen, Zhengming, Jurczak, Wojciech, Auer, Rebecca, Chmielowska, Ewa, Stilgenbauer, Stephan, Bloehdorn, Johannes, Portell, Craig, Williams, Michael E., Dreyling, Martin, Barr, Paul M., Chen-Kiang, Selina, DiLiberto, Maurizio, Furman, Richard R., and Blum, Kristie A.

Published
2016
Full Text
View/download PDF

93. ALK‐rearranged CD30‐positive poorly differentiated lung adenocarcinoma, mimicking anaplastic large‐cell lymphoma.

Author

George, Giby V, Wallace, Danielle S, Wang, Ying, Carney, John, Elsadawi, Murad, Burack, W Richard, Evans, Andrew G, Barr, Paul M, Velez, Moises J, and El Hussein, Siba

Subjects
ANAPLASTIC large-cell lymphoma, CAUDA equina syndrome
Abstract

This article discusses a case of a 64-year-old man who presented with back pain and cough. Imaging revealed masses in the chest and abdomen, as well as pleural effusions. Pathological examination of the tissue revealed a poorly differentiated malignant neoplasm that initially appeared to be anaplastic large-cell lymphoma (ALCL) based on immunohistochemical staining. However, further molecular testing confirmed a diagnosis of ALK-rearranged lung adenocarcinoma. The patient has responded to ALK-inhibitor therapy. The article emphasizes the importance of careful interpretation of immunohistochemical stains in cases of poorly differentiated ALK+/CD30+ neoplasms. [Extracted from the article]

Published
2024
Full Text
View/download PDF

95. Shock to the system? An HFMA survey reveals CFOs' deep concerns for major service lines this decade, but some are prepared to embrace the coming disruption

Author

Barr, Paul

Subjects
Hospitals -- Management -- United States, Chief financial officers -- Management, Company business management, Business, Health care industry, Healthcare Financial Management Association -- Surveys
Abstract

Haven Health may have withered on the vine. Google Health may have been broken up. But a disruption of healthcare's business model still is likely coming, and the actions hospital [...]

Published
2021

97. Implementation of the uterine fibroids Option Grid patient decision aids across five organizational settings: a randomized stepped-wedge study protocol

Author

Scalia, Peter, Durand, Marie-Anne, Forcino, Rachel C., Schubbe, Danielle, Barr, Paul J., O’Brien, Nancy, O’Malley, A. James, Foster, Tina, Politi, Mary C., Laughlin-Tommaso, Shannon, Banks, Erika, Madden, Tessa, Anchan, Raymond M., Aarts, Johanna W. M., Velentgas, Priscilla, Balls-Berry, Joyce, Bacon, Carla, Adams-Foster, Monica, Mulligan, Carrie Cahill, Venable, Sateria, Cochran, Nancy E., and Elwyn, Glyn

Published
2019
Full Text
View/download PDF

98. Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.

Author

Wallace, Danielle S., Rowland, Chris, Hill, Brian T., Baran, Andrea M., Casulo, Carla, Reagan, Patrick M., Winter, Allison, Karmali, Reem, Winter, Jane N., Gordon, Leo I., Bui, Andrew, Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Friedberg, Jonathan W., Ma, Shuo, and Barr, Paul M.

Subjects
BRUTON tyrosine kinase, VENETOCLAX, MANTLE cell lymphoma
Abstract

Patients with mantle cell lymphoma require treatment options following BTK inhibition, as evidenced by the 14.6 months median OS rate from initiation of BTK inhibitor in the recently published SCHOLAR-2 analysis [[11]]. Nine patients were refractory to prior therapy, 9 had previously received a BTK inhibitor (BTKi) including 7 who were refractory to BTKi and there were 3 who had progressive lymphoma following chimeric antigen receptor T-cell (CAR-T) therapy. Novel agents such as the Bruton's tyrosine kinase (BTK) inhibitors have improved outcomes for patients with mantle cell lymphoma (MCL) and continue to change treatment paradigms [[1]]. [Extracted from the article]

Published
2023
Full Text
View/download PDF

99. Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials

Author

Rutherford, Sarah C., primary, Yin, Jun, additional, Pederson, Levi, additional, Perez Burbano, Gabriela, additional, LaPlant, Betsy, additional, Shadman, Mazyar, additional, Li, Hongli, additional, LeBlanc, Michael L., additional, Kenkre, Vaishalee P., additional, Hong, Fangxin, additional, Blum, Kristie A., additional, Dockter, Travis, additional, Martin, Peter, additional, Jung, Sin-Ho, additional, Grant, Barbara, additional, Rosenbaum, Cara, additional, Ujjani, Chaitra, additional, Barr, Paul M., additional, Unger, Joseph M., additional, Cheson, Bruce D., additional, Bartlett, Nancy L., additional, Kahl, Brad, additional, Friedberg, Jonathan W., additional, Mandrekar, Sumithra J., additional, and Leonard, John P., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results